APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nucleic Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Nucleic Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025192 pages

Choose your research edition.

Industry ResearchNucleic Vaccine Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Nucleic Vaccine Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Nucleic Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nucleic Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Nucleic Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Nucleic Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Nucleic Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nucleic Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nucleic Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Nucleic Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nucleic Vaccine include CNBG, Zhifei Shengwu, Walvax Biotechnology, Sanofi, Liaoning Chengda, CanSinoBIO, BioKangtai, Hualan Bio and GSK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nucleic Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nucleic Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nucleic Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nucleic Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Nucleic Vaccine Segment by Company

CNBG

Zhifei Shengwu

Walvax Biotechnology

Sanofi

Liaoning Chengda

CanSinoBIO

BioKangtai

Hualan Bio

GSK

Fosun Pharma

Moderna

Inovio

CureVac

Nucleic Vaccine Segment by Type

Preventive Nucleic Vaccine

Therapeutic Nucleic Vaccine

Nucleic Vaccine Segment by Application

Hospital

Clinic

Others

Nucleic Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nucleic Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleic Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nucleic Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nucleic Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Nucleic Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Nucleic Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Nucleic Vaccine Industry Trends Table 2. Nucleic Vaccine Industry Drivers Table 3. Nucleic Vaccine Industry Opportunities and Challenges Table 4. Nucleic Vaccine Industry Restraints Table 5. Global Nucleic Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Nucleic Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Nucleic Vaccine Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Nucleic Vaccine Sales Market Share by Manufacturers Table 9. Global Nucleic Vaccine Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Nucleic Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Nucleic Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Nucleic Vaccine Manufacturers, Product Type & Application Table 13. Global Nucleic Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Nucleic Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Preventive Nucleic Vaccine Table 17. Major Manufacturers of Therapeutic Nucleic Vaccine Table 18. Global Nucleic Vaccine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Nucleic Vaccine Sales by Type (2021-2026) & (k units) Table 20. Global Nucleic Vaccine Sales by Type (2027-2032) & (k units) Table 21. Global Nucleic Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Nucleic Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Nucleic Vaccine Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Nucleic Vaccine Revenue by Type (2021-2026) & (k units) Table 25. Global Nucleic Vaccine Revenue by Type (2027-2032) & (k units) Table 26. Global Nucleic Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Nucleic Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Others Table 31. Global Nucleic Vaccine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Nucleic Vaccine Sales by Application (2021-2026) & (k units) Table 33. Global Nucleic Vaccine Sales by Application (2027-2032) & (k units) Table 34. Global Nucleic Vaccine Sales Market Share by Application (2021-2026) Table 35. Global Nucleic Vaccine Sales Market Share by Application (2027-2032) Table 36. Global Nucleic Vaccine Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Nucleic Vaccine Revenue by Application (2021-2026) & (k units) Table 38. Global Nucleic Vaccine Revenue by Application (2027-2032) & (k units) Table 39. Global Nucleic Vaccine Revenue Market Share by Application (2021-2026) Table 40. Global Nucleic Vaccine Revenue Market Share by Application (2027-2032) Table 41. Global Nucleic Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Nucleic Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global Nucleic Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Nucleic Vaccine Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Nucleic Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Nucleic Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Nucleic Vaccine Sales by Country (2021-2026) & (k units) Table 48. North America Nucleic Vaccine Sales by Country (2027-2032) & (k units) Table 49. Europe Nucleic Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Nucleic Vaccine Sales by Country (2021-2026) & (k units) Table 51. Europe Nucleic Vaccine Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Nucleic Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Nucleic Vaccine Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Nucleic Vaccine Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Nucleic Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Nucleic Vaccine Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Nucleic Vaccine Sales by Country (2027-2032) & (k units) Table 58. Global Nucleic Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Nucleic Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Nucleic Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Nucleic Vaccine Revenue Market Share by Region (2021-2026) Table 62. Global Nucleic Vaccine Revenue Market Share by Region (2027-2032) Table 63. CNBG Company Information Table 64. CNBG Business Overview Table 65. CNBG Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. CNBG Nucleic Vaccine Product Portfolio Table 67. CNBG Recent Development Table 68. Zhifei Shengwu Company Information Table 69. Zhifei Shengwu Business Overview Table 70. Zhifei Shengwu Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Zhifei Shengwu Nucleic Vaccine Product Portfolio Table 72. Zhifei Shengwu Recent Development Table 73. Walvax Biotechnology Company Information Table 74. Walvax Biotechnology Business Overview Table 75. Walvax Biotechnology Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Walvax Biotechnology Nucleic Vaccine Product Portfolio Table 77. Walvax Biotechnology Recent Development Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Sanofi Nucleic Vaccine Product Portfolio Table 82. Sanofi Recent Development Table 83. Liaoning Chengda Company Information Table 84. Liaoning Chengda Business Overview Table 85. Liaoning Chengda Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Liaoning Chengda Nucleic Vaccine Product Portfolio Table 87. Liaoning Chengda Recent Development Table 88. CanSinoBIO Company Information Table 89. CanSinoBIO Business Overview Table 90. CanSinoBIO Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. CanSinoBIO Nucleic Vaccine Product Portfolio Table 92. CanSinoBIO Recent Development Table 93. BioKangtai Company Information Table 94. BioKangtai Business Overview Table 95. BioKangtai Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. BioKangtai Nucleic Vaccine Product Portfolio Table 97. BioKangtai Recent Development Table 98. Hualan Bio Company Information Table 99. Hualan Bio Business Overview Table 100. Hualan Bio Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Hualan Bio Nucleic Vaccine Product Portfolio Table 102. Hualan Bio Recent Development Table 103. GSK Company Information Table 104. GSK Business Overview Table 105. GSK Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. GSK Nucleic Vaccine Product Portfolio Table 107. GSK Recent Development Table 108. Fosun Pharma Company Information Table 109. Fosun Pharma Business Overview Table 110. Fosun Pharma Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Fosun Pharma Nucleic Vaccine Product Portfolio Table 112. Fosun Pharma Recent Development Table 113. Moderna Company Information Table 114. Moderna Business Overview Table 115. Moderna Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Moderna Nucleic Vaccine Product Portfolio Table 117. Moderna Recent Development Table 118. Inovio Company Information Table 119. Inovio Business Overview Table 120. Inovio Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Inovio Nucleic Vaccine Product Portfolio Table 122. Inovio Recent Development Table 123. CureVac Company Information Table 124. CureVac Business Overview Table 125. CureVac Nucleic Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. CureVac Nucleic Vaccine Product Portfolio Table 127. CureVac Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Nucleic Vaccine Distributors List Table 131. Nucleic Vaccine Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Nucleic Vaccine Product Image Figure 2. Global Nucleic Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nucleic Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Nucleic Vaccine Sales (2021-2032) & (k units) Figure 5. Global Nucleic Vaccine Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Nucleic Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Preventive Nucleic Vaccine Image Figure 9. Therapeutic Nucleic Vaccine Image Figure 10. Global Nucleic Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Nucleic Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Nucleic Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Nucleic Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Nucleic Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Nucleic Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Others Image Figure 19. Global Nucleic Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Nucleic Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Nucleic Vaccine Sales Market Share by Application (2021-2032) Figure 22. Global Nucleic Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Nucleic Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Nucleic Vaccine Revenue Market Share by Application (2021-2032) Figure 25. North America Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Nucleic Vaccine Sales Market Share by Country (2021-2032) Figure 27. U.S. Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Nucleic Vaccine Sales Market Share by Country (2021-2032) Figure 32. Germany Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Nucleic Vaccine Sales Market Share by Country (2021-2032) Figure 39. China Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Nucleic Vaccine Sales Market Share by Country (2021-2032) Figure 47. Brazil Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Nucleic Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Nucleic Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Nucleic Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Nucleic Vaccine Revenue (2021-2032) & (US$ Million) Figure 58. North America Nucleic Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Nucleic Vaccine Revenue (2021-2032) & (US$ Million) Figure 60. Europe Nucleic Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Nucleic Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Nucleic Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Nucleic Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Nucleic Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Nucleic Vaccine Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Nucleic Vaccine Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Nucleic Vaccine
  • Therapeutic Nucleic Vaccine
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • CNBG
  • Zhifei Shengwu
  • Walvax Biotechnology
  • Sanofi
  • Liaoning Chengda
  • CanSinoBIO
  • BioKangtai
  • Hualan Bio
  • GSK
  • Fosun Pharma
  • Moderna
  • Inovio
  • CureVac

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nucleic Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nucleic Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Nucleic Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Nucleic Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Nucleic Vaccine Market Dynamics
  1. 2.1 Nucleic Vaccine Industry Trends
  2. 2.2 Nucleic Vaccine Industry Drivers
  3. 2.3 Nucleic Vaccine Industry Opportunities and Challenges
  4. 2.4 Nucleic Vaccine Industry Restraints
3 Nucleic Vaccine Market by Manufacturers
  1. 3.1 Global Nucleic Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Nucleic Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Nucleic Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Nucleic Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Nucleic Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Nucleic Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Nucleic Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Nucleic Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Nucleic Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Nucleic Vaccine Tier 1, Tier 2, and Tier 3
4 Nucleic Vaccine Market by Type
  1. 4.1 Nucleic Vaccine Type Introduction
  2. 4.1.1 Preventive Nucleic Vaccine
  3. 4.1.2 Therapeutic Nucleic Vaccine
  4. 4.2 Global Nucleic Vaccine Sales by Type
  5. 4.2.1 Global Nucleic Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Nucleic Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Nucleic Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Nucleic Vaccine Revenue by Type
  9. 4.3.1 Global Nucleic Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Nucleic Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Nucleic Vaccine Revenue Market Share by Type (2021-2032)
5 Nucleic Vaccine Market by Application
  1. 5.1 Nucleic Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Nucleic Vaccine Sales by Application
  6. 5.2.1 Global Nucleic Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nucleic Vaccine Sales by Application (2021-2032)
  8. 5.2.3 Global Nucleic Vaccine Sales Market Share by Application (2021-2032)
  9. 5.3 Global Nucleic Vaccine Revenue by Application
  10. 5.3.1 Global Nucleic Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Nucleic Vaccine Revenue by Application (2021-2032)
  12. 5.3.3 Global Nucleic Vaccine Revenue Market Share by Application (2021-2032)
6 Global Nucleic Vaccine Sales by Region
  1. 6.1 Global Nucleic Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nucleic Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Nucleic Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Nucleic Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nucleic Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Nucleic Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Nucleic Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Nucleic Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Nucleic Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Nucleic Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Nucleic Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Nucleic Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Nucleic Vaccine Revenue by Region
  1. 7.1 Global Nucleic Vaccine Revenue by Region
  2. 7.1.1 Global Nucleic Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Nucleic Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Nucleic Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Nucleic Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Nucleic Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Nucleic Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Nucleic Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Nucleic Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Nucleic Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Nucleic Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Nucleic Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Nucleic Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CNBG
  2. 8.1.1 CNBG Company Information
  3. 8.1.2 CNBG Business Overview
  4. 8.1.3 CNBG Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CNBG Nucleic Vaccine Product Portfolio
  6. 8.1.5 CNBG Recent Developments
  7. 8.2 Zhifei Shengwu
  8. 8.2.1 Zhifei Shengwu Company Information
  9. 8.2.2 Zhifei Shengwu Business Overview
  10. 8.2.3 Zhifei Shengwu Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zhifei Shengwu Nucleic Vaccine Product Portfolio
  12. 8.2.5 Zhifei Shengwu Recent Developments
  13. 8.3 Walvax Biotechnology
  14. 8.3.1 Walvax Biotechnology Company Information
  15. 8.3.2 Walvax Biotechnology Business Overview
  16. 8.3.3 Walvax Biotechnology Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Walvax Biotechnology Nucleic Vaccine Product Portfolio
  18. 8.3.5 Walvax Biotechnology Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Nucleic Vaccine Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Liaoning Chengda
  26. 8.5.1 Liaoning Chengda Company Information
  27. 8.5.2 Liaoning Chengda Business Overview
  28. 8.5.3 Liaoning Chengda Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Liaoning Chengda Nucleic Vaccine Product Portfolio
  30. 8.5.5 Liaoning Chengda Recent Developments
  31. 8.6 CanSinoBIO
  32. 8.6.1 CanSinoBIO Company Information
  33. 8.6.2 CanSinoBIO Business Overview
  34. 8.6.3 CanSinoBIO Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CanSinoBIO Nucleic Vaccine Product Portfolio
  36. 8.6.5 CanSinoBIO Recent Developments
  37. 8.7 BioKangtai
  38. 8.7.1 BioKangtai Company Information
  39. 8.7.2 BioKangtai Business Overview
  40. 8.7.3 BioKangtai Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 BioKangtai Nucleic Vaccine Product Portfolio
  42. 8.7.5 BioKangtai Recent Developments
  43. 8.8 Hualan Bio
  44. 8.8.1 Hualan Bio Company Information
  45. 8.8.2 Hualan Bio Business Overview
  46. 8.8.3 Hualan Bio Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hualan Bio Nucleic Vaccine Product Portfolio
  48. 8.8.5 Hualan Bio Recent Developments
  49. 8.9 GSK
  50. 8.9.1 GSK Company Information
  51. 8.9.2 GSK Business Overview
  52. 8.9.3 GSK Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GSK Nucleic Vaccine Product Portfolio
  54. 8.9.5 GSK Recent Developments
  55. 8.10 Fosun Pharma
  56. 8.10.1 Fosun Pharma Company Information
  57. 8.10.2 Fosun Pharma Business Overview
  58. 8.10.3 Fosun Pharma Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Fosun Pharma Nucleic Vaccine Product Portfolio
  60. 8.10.5 Fosun Pharma Recent Developments
  61. 8.11 Moderna
  62. 8.11.1 Moderna Company Information
  63. 8.11.2 Moderna Business Overview
  64. 8.11.3 Moderna Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Moderna Nucleic Vaccine Product Portfolio
  66. 8.11.5 Moderna Recent Developments
  67. 8.12 Inovio
  68. 8.12.1 Inovio Company Information
  69. 8.12.2 Inovio Business Overview
  70. 8.12.3 Inovio Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Inovio Nucleic Vaccine Product Portfolio
  72. 8.12.5 Inovio Recent Developments
  73. 8.13 CureVac
  74. 8.13.1 CureVac Company Information
  75. 8.13.2 CureVac Business Overview
  76. 8.13.3 CureVac Nucleic Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CureVac Nucleic Vaccine Product Portfolio
  78. 8.13.5 CureVac Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nucleic Vaccine Value Chain Analysis
  2. 9.1.1 Nucleic Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nucleic Vaccine Production Mode & Process
  6. 9.2 Nucleic Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nucleic Vaccine Distributors
  9. 9.2.3 Nucleic Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst